Article · 20 May 2025
Brief reportPublished 22 Jul 2016
Pharmacogenomics and the prevention of vascular complications in diabetes mellitus
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
While the majority of patients benefit from front-line therapies for diabetes and dyslipidemia, others present with diminished responses. These differences in drug efficacy appear to be due, in large part, to genetic polymorphisms affecting pharmacokinetics and drug-target interactions. Many studies have been conducted in an attempt to elucidate the pharmacogenetic relationship between a wide range of polymorphisms and their effects on responsiveness to statins, hypoglycemics, insulin sensitizers, antihypertensives and antioxidants. Regarding most polymorphisms, the results of association studies have not been validated consistently across different population groups. This review will present some of these pharmacogenetic relationships, focusing on the haptoglobin polymorphism and the responsiveness to vitamin E supplementation.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Dan Farbstein”
- BylineArticles whose byline prints “Andrew P Levy”